Germanyboehringer-ingelheim.com
Owner Investor / Financier Operator Developer
Boehringer Ingelheim is a privately held, research-driven biopharmaceutical company headquartered in Ingelheim am Rhein, Germany. Founded in 1885, it operates globally across human pharmaceuticals and animal health, developing, manufacturing, and supplying prescription medicines, biologics, and veterinary vaccines and therapeutics.
The company’s R&D spans respiratory and fibrotic diseases, cardiovascular and metabolic conditions, immunology, oncology, and central nervous system and retinal disorders. In animal health, it serves both companion animals and livestock with prevention and treatment solutions.
Boehringer Ingelheim maintains significant development and manufacturing capabilities, including large-scale biopharmaceutical production and process development. Through its contract manufacturing services, it supports third parties with clinical and commercial supply of therapeutic proteins and antibodies. The company also operates a global network of research and production sites in Europe, the United States, and Asia, and consistently reinvests a substantial share of its revenue into R&D.
chemXplore tracks 6 projects involving Boehringer Ingelheim, of which one is active.
Besides this one, the record holds 5 completed projects.
Closest to start-up first.
The 5 that are completed, on hold or cancelled are in the record. See all 6 in chemXplore →
Revenue rose 48% to $23.0bn driven by Mounjaro and Zepbound; updated 2026 revenue guidance to $85–87bn; retatrutide Phase 3 package complete supporting a Q1 2027 BLA.
First-in-class oral PDE4B inhibitor approved for adults with IPF and PPF after Phase III trials showed slower lung function decline and a favourable tolerability profile.
Phase II starts for a potential first‑in‑class triple GLP‑1/GIP/NPY2 receptor agonist targeting weight, satiety and central hunger signalling; study includes dose finding and safety/efficacy evaluation.
Three Phase III trials will test DLL3-targeting obrixtamig in SCLC and epNEC, and HER2 TKI zongertinib as adjuvant therapy in resectable HER2‑mutant NSCLC.
Phase III data show targeted visceral and liver fat reductions with minimal lean mass loss and sustained weight loss in obesity and MASLD populations.
CHRYSALIS-2 Phase1/1b (n=49): first-line atypical EGFR‑mutant NSCLC showed ORR 57%; 3‑yr OS 55%, 4‑yr OS 46%; 41% remained on treatment ≥2 years; safety consistent with prior reports.
CHMP recommends EU approval after Phase III FIBRONEER trials showed slowed FVC decline in IPF and PPF; oral preferential PDE4B inhibitor already authorised in multiple countries.
First oral PDE4B inhibitor shows slowed FVC decline in FIBRONEER Phase III; pooled analysis showed 59% nominal death reduction. Common AE: diarrhea; EU/UK reviews ongoing.
